Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Newest Articles
    • Current Issue
    • Methods & Resources
    • Author Interviews
    • Archive
    • Subjects
  • Collections
  • Submit
    • Submit a Manuscript
    • Author Guidelines
    • License, Copyright, Fee
    • FAQ
    • Why submit
  • About
    • About Us
    • Editors & Staff
    • Board Members
    • Licensing and Reuse
    • Reviewer Guidelines
    • Privacy Policy
    • Advertise
    • Contact Us
    • LSA LLC
  • Alerts
  • Other Publications
    • EMBO Press
    • The EMBO Journal
    • EMBO reports
    • EMBO Molecular Medicine
    • Molecular Systems Biology
    • Rockefeller University Press
    • Journal of Cell Biology
    • Journal of Experimental Medicine
    • Journal of General Physiology
    • Journal of Human Immunity
    • Cold Spring Harbor Laboratory Press
    • Genes & Development
    • Genome Research

User menu

  • My alerts

Search

  • Advanced search
Life Science Alliance
  • Other Publications
    • EMBO Press
    • The EMBO Journal
    • EMBO reports
    • EMBO Molecular Medicine
    • Molecular Systems Biology
    • Rockefeller University Press
    • Journal of Cell Biology
    • Journal of Experimental Medicine
    • Journal of General Physiology
    • Journal of Human Immunity
    • Cold Spring Harbor Laboratory Press
    • Genes & Development
    • Genome Research
  • My alerts
Life Science Alliance

Advanced Search

  • Home
  • Articles
    • Newest Articles
    • Current Issue
    • Methods & Resources
    • Author Interviews
    • Archive
    • Subjects
  • Collections
  • Submit
    • Submit a Manuscript
    • Author Guidelines
    • License, Copyright, Fee
    • FAQ
    • Why submit
  • About
    • About Us
    • Editors & Staff
    • Board Members
    • Licensing and Reuse
    • Reviewer Guidelines
    • Privacy Policy
    • Advertise
    • Contact Us
    • LSA LLC
  • Alerts
  • Follow LSA on Bluesky
  • Follow lsa Template on Twitter
Research Article
Source Data
Transparent Process
Open Access

Angioplasty induces epigenomic remodeling in injured arteries

Mengxue Zhang, Go Urabe, Hatice Gulcin Ozer, Xiujie Xie, Amy Webb, Takuro Shirasu, Jing Li, Renzhi Han, K Craig Kent, View ORCID ProfileBowen Wang  Correspondence email, View ORCID ProfileLian-Wang Guo  Correspondence email
Mengxue Zhang
1Department of Surgery, School of Medicine, University of Virginia, Charlottesville, VA, USA
Roles: Data curation, Investigation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Go Urabe
1Department of Surgery, School of Medicine, University of Virginia, Charlottesville, VA, USA
Roles: Data curation, Formal analysis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hatice Gulcin Ozer
2Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH, USA
Roles: Formal analysis, Investigation, Visualization
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiujie Xie
1Department of Surgery, School of Medicine, University of Virginia, Charlottesville, VA, USA
Roles: Data curation, Methodology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amy Webb
2Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH, USA
Roles: Formal analysis, Investigation, Visualization
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takuro Shirasu
1Department of Surgery, School of Medicine, University of Virginia, Charlottesville, VA, USA
Roles: Data curation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jing Li
1Department of Surgery, School of Medicine, University of Virginia, Charlottesville, VA, USA
Roles: Data curation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Renzhi Han
3Department of Surgery, College of Medicine, The Ohio State University, Columbus, OH, USA
Roles: Formal analysis, Supervision, Funding acquisition, Investigation, Methodology, Gene editing methodology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
K Craig Kent
1Department of Surgery, School of Medicine, University of Virginia, Charlottesville, VA, USA
Roles: Supervision, Funding acquisition
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bowen Wang
1Department of Surgery, School of Medicine, University of Virginia, Charlottesville, VA, USA
Roles: Conceptualization, Formal analysis, Investigation, Writing—review and editing
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Bowen Wang
  • For correspondence: bw2pw@virginia.edu
Lian-Wang Guo
1Department of Surgery, School of Medicine, University of Virginia, Charlottesville, VA, USA
4Department of Molecular Physiology and Biological Physics, School of Medicine, University of Virginia, Charlottesville, VA, USA
5Robert M Berne Cardiovascular Research Center, University of Virginia, Charlottesville, VA, USA
Roles: Conceptualization, Supervision, Funding acquisition, Project administration, Writing—original draft, review, and editing
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Lian-Wang Guo
  • For correspondence: lg8zr@virginia.edu
Published 15 February 2022. DOI: 10.26508/lsa.202101114
  • Article
  • Figures & Data
  • Info
  • Metrics
  • Reviewer Comments
  • PDF
Loading

Article Figures & Data

Figures

  • Supplementary Materials
  • Figure S1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S1. Angioplasty induces expression of pro-IH markers in balloon-injured rat carotid arteries.

    The samples are equivalents of those used for ChIPseq in Fig 1. NRP2 and UHRF1 are pro-IH markers established in previous reports using the same model of rat common carotid artery balloon angioplasty. qRT-PCR data were normalized using the ΔΔCT-log2 approach. Quantification: Mean ± SD; n = 3 repeats; unpaired t test, *P < 0.05. r.u., relative unit.

  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1. Injury-induced genome-wide changes of ChIPseq reading in rat common carotid arteries.

    Balloon-injured rat left common carotid arteries and contralateral arteries (uninjured sham control) were collected (each group pooled from 50 rats) at day 7 post angioplasty and snap-frozen for use in ChIPseq experiments. (A) ChIPseq heat map showing binding density of BRD4, H3K27ac, H3K27me3, or H3K4me1. ChIPseq signal anchors a 10 kb center region with 5 kb flanking on either side of the transcription start site. Hierarchical clustering highlights injury-induced increase of H3K27me3 ChIPseq signal (Cluster-1) and non-overlap between H3K27me3 and H3K27ac. (B) Functional enrichment of Clusters 1 and 2. Presented is dot plot of Top 10 molecular function (MF) gene ontology (GO) terms with color as adjusted P-value and size of dot as gene ratio. Enrichment analysis was performed by clusterProfiler.

  • Figure S2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S2. Gene oncology (GO) analysis (including all three ChIPseq peak clusters).

    GO enrichment was analyzed for molecular function (MF) terms, which were ranked by adjusted P-value (or Q value), a modified Fisher exact P-value. Gene ratio refers to the proportion of the selected genes versus the total genes belonging to the given term.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2. Comparison of ChIPseq peak coverage between injured and uninjured arteries.

    (A) Bean plot showing genome-wide distribution of BRD4 or histone mark ChIPseq peak values. P-values from Wilcox test are presented above the plots. (B) Scatter plot showing injury-induced change in binding density (ChIPseq reads) of BRD4 or a histone mark. Red and blue indicates increase and decrease, respectively, with a twofold cutoff.

  • Figure S3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S3. Overlap of ChIPseq peaks.

    (A) Venn diagrams showing overlap of BRD4 and H3K27ac peaks. (B) Venn diagrams showing overlap of BRD4 and H3K4me1 peaks. (C) Venn diagrams showing overlap of H3K27ac and H3K4me1 peaks. Rat carotid artery balloon angioplasty, sample collection, ChIPseq, and data analysis were performed as described for Fig 1. Diagrams in (A) were used in our recent publication (PMID 33768129). Note: Whereas BRD4 and H3K27ac are both associated with active enhancers, H3K4me1 can be found with active, inactive, and also poised enhancers.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3. Injury-induced H3K27me3 enrichment at anti-proliferative gene P57 and BRD4/H3K27ac enrichment at pro-proliferative gene Ccnd1.

    ChIPseq was performed as described for Fig 1. Integrative genomics viewer (IGV) tracks show comparison of normalized ChIPseq peaks between injured arteries (+, light color) and uninjured sham-control arteries (−, dark color). Boxes highlight the regions where the binding of H3K27ac and BRD4 increased after arterial injury. Non-specific input confirms low background noise. (A, B, C) IGV profiles of ChIPseq peaks illustrating loci-specific binding density of chromatin marks. (D) Schematic proposition of H3K27me3 and H3K27ac redistribution between anti-proliferative (e.g., P57) and pro-proliferative genes (e.g., Uhrf1 and Ccnd1), based on the artery tissue ChIPseq analysis. Note: The cartoon does not represent the true genomic locations of Uhrf1 and Ccnd1.

  • Figure S4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S4. IGV profiles of ChIPseq peaks at Bmp4 and Nrp2.

    Shown are ChIPseq peaks (or binding density) in injured arteries (+, light color) and uninjured sham control arteries (−, dark color). BMP4 represents an anti-proliferative factor; NRP2 represents a pro-proliferative factor. Nonspecific input indicates low background noise. Box indicates an intronic enhancer region.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4. Regulation of EZH2 expression by BRD4 in smooth muscle cells (SMCs) in vitro.

    (A, B) BRD4 ChIPseq peaks at Ezh2 (B is the zoom-in version of A). Boxes highlight one enhancer region at the distal end of Ezh2 promoter and another within an intron. Genomic coordinates of Box-I: chr4 142018866-142019623; Box-II: chr4 142017383-142017905. Mean coverage of ChIPseq peaks (indicative of BRD4 binding dencity) within each box is labeled, with an arrow pointing to the box. Note the H3K4me1 signal is low relative to H3K27ac of the same scale. (C) Effect of Cas9-mediated enhancer deletion (genome editing) on EZH2 expression in rat primary aortic SMCs. sg, small guide RNA. The pair of sgRNAs flank an Ezh2 intronic region, that is, +1,161 bp to +218 bp from the transcription start site. Quantification: Mean ± SEM; n = 3 independent experiments; paired t test, *P < 0.05. (D) Disruption of EZH2 expression through a non-genome-editing, dead Cas9 (dCas9)-facilitated approach. Rat primary aortic SMCs were used. The same sgRNAs (as that in C) were used. Quantification: Mean ± SEM; n = 3 independent experiments; paired t test, *P < 0.05. (E, F) Effect of BRD4 silencing on EZH2 expression. BRD2, BRD3, or BRD4 was silenced with their specific siRNAs (validated in our recent reports) (Wang et al, 2015; Zhang et al, 2019). Cultured rat aortic SMCs were starved for 6 h before transfection with the siRNA for BRD2, 3, or 4 overnight. The cells recovered (without transfection reagents) for 24 and 48 h before RNA and protein extraction, respectively. EZH2 protein and mRNA were measured with Western blot and qRT-PCR (normalized by ΔΔCT-log2) assays. Quantification: Mean ± SEM; n = 3 independent experiments; one-way ANOVA with Bonferroni test, *P < 0.05 compared with the scrambled-sequence siRNA control. (G) Schematic depicting BRD4 and its co-localization with H3K27ac at Ezh2 that promote Ezh2 transcription.

    Source data are available for this figure.

    Source Data for Figure S4[LSA-2021-01114_SdataF4_F8_F9_FS6.pdf]

  • Figure S5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S5. Negative control of enhancer deletion via genome-editing CRISPR.

    Genome-editing CRISPR was performed as described for Fig 4C except that the sgRNAs targeted an upstream region ∼50 kb away from the Ezh2 transcription start site. n.s., not significant.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5. Smooth muscle cell-specific BRD4 KO reduces IH in wire-injured mouse femoral arteries.

    (A) Cartoon of mouse common femoral artery where wire injury was made to induce IH. (B) Diagram indicating the time line for tamoxifen feeding, wire injury, and tissue collection. (C) Immunofluorescence confirming tamoxifen-induced BRD4 KO in mouse arteries. Scale bar: 50 μm. (D) Comparison of IH between WT (Brd4fl/fl) and smooth muscle cell-specific BRD4 KO (Brd4fl/fl; Myh11-CreERT2) mice. Neointima thickness is demarcated by arrow heads. IH is normalized as intima/media area (I/M) ratio. Scale bar: 50 μm. (E) Quantification: Mean ± SEM; n = 4–7 mice, as indicated by the data points in scatter plots. Statistics: one-way ANOVA with Bonferroni test; **P < 0.01, ***P < 0.001; r.u., relative unit.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6. Reduced EZH2 and H3K27me3 in mouse arteries of smooth muscle cell-specific BRD4 KO.

    Tamoxifen-induced BRD4 KO and wire injury were performed as described for Fig 5. (A, B, C, D) Immunofluorescence shows comparison of EZH2 (A, B) or its catalytic product H3K27me3 (C, D) between WT and BRD4 conditional KO mice. Neointima is demarcated by arrow heads. Fluorescence intensity was normalized to cell number (DAPI-stained nuclei). Scale bar: 50 μm. Quantification: Mean ± SEM; n = 5 mice as indicated by the data points in scatter plots. Statistics: nonparametric Mann–Whitney test following Shapiro–Wilk normality determination, *P < 0.05, **P < 0.01; r.u., relative unit.

  • Figure S6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S6. Angioplasty-induced EZH2 up-regulation in rat carotid arteries.

    (A, B) The samples are equivalents of those used for ChIPseq in Fig 1. qRT-PCR data were normalized using the ΔΔCT-log2 approach. Quantification: Mean ± SD; n = 3 repeats; unpaired t test, P = 0.15. r.u., relative unit.

    Source data are available for this figure.

    Source Data for Figure S6[LSA-2021-01114_SdataF4_F8_F9_FS6.pdf]

  • Figure 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 7. Effect of EZH1 or EZH2 gain- or loss-of-function on IH in balloon-injured rat carotid arteries.

    (A) Picture illustrating intraluminal infusion of lentivirus to express a gene in the balloon-injured rat carotid artery wall. A cannula (yellow device) connected to a syringe was used to inject lentivirus to the carotid artery lumen for infusion into the injured artery wall. (B) Gain of function. EZH overexpression (EZH1 or EZH2 each in fusion with GFP) in the injured rat carotid artery wall was accomplished via intraluminal infusion of lentivirus. Arteries were collected at post-injury day 14 for histology. Immunostained cross sections indicate increase of H3K27me3 in EZH-overexpressing arteries versus Lenti-GFP controls, predominantly in the neointima layer. A, adventitia. M, media. N, neointima. Scale bar: 50 μm. Quantification: Mean ± SEM; n = 3 rats; one-way ANOVA with Bonferroni test, *P < 0.05. No significance between Lenti-EZH1 and Lenti-GFP. (C) EZH gain-of-function exacerbates IH (measured as I/M ratio). Neointima is demarcated between arrow heads. Scale bar: 50 μm. Quantification: Mean ± SEM; n = 4–5 rats; one-way ANOVA with Bonferroni test, *P < 0.05. (D) Picture depicting perivascular application of pan-EZH inhibitor UNC1999 dispersed in a thermosensitive hydrogel. (E) EZH loss of function (inhibition) mitigates IH. Arteries were collected at post-injury day 14. Scale bar: 50 μm. Quantification: Mean ± SEM; n = 4–5 rats; unpaired t test, *P < 0.05.

  • Figure S7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S7. Overlap of proliferating cell nuclear antigen (PCNA) with H3K27me3 in the neointima.

    Rat common carotid arteries were balloon-injured and collected on day 14 after injury. Cross sections were immunostained for H3k27me3 or PCNA. Immunofluorescence shows PCNA colocalization with H3K27me3 in DAPI-stained nuclei. Neointima is indicated between arrow heads. Scale bar: 50 μm.

  • Figure S8.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S8. pan-EZH inhibitor mitigates smooth muscle cell proliferation and migration.

    MOVAS cells were cultured, starved for 6 h, pretreated with vehicle (DMSO) or the pan-EZH1/2 inhibitor UNC1999 for 2 h, and then stimulated with PDGF-BB (final 20 ng/ml). (A, B) For proliferation (A) and migration (B, 5 μM UNC1999) assays, cells were harvested at 72 h or imaged at 24 h after PDGF-BB stimulation, respectively. For the scratch assay, the calcein dye was added at the end of 24 h PDGF treatment to illuminate the cells. The yellow lines on the 0 h picture demarcate the original scratched cell-free gap.

  • Figure 8.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 8. Effect of EZH1 or EZH2 gain- or loss-of-function on smooth muscle cell proliferation and migration.

    (A, B, C, D) Loss of function. Silencing efficiency is indicated by Western blots (A). For proliferation (B) and migration (C, D) assays, cells were harvested at 72 h or imaged at 24 h after PDGF-BB stimulation, respectively. Scr, scrambled. NS, not significant. (E, F, G, H) Gain of function. EZH1 or EZH2 overexpression is shown in Western blots (E). * marks the recombinant protein in fusion with GFP; the lower band is endogenous protein. For proliferation (F) and migration (G, H) assays, cells were harvested at 72 h or imaged at 24 h after PDGF-BB stimulation, respectively. Quantification: Mean ± SEM; n = 3 independent experiments. Statistics: one-way ANOVA with Bonferroni test, *P < 0.05.

    Source data are available for this figure.

    Source Data for Figure 8[LSA-2021-01114_SdataF4_F8_F9_FS6.pdf]

  • Figure 9.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 9. Effect of EZH1 or EZH2 gain- or loss-of-function on target gene expression.

    MOVAS cells were pretreated with the pan-EZH1/2 inhibitor UNC1999 (5 μM) for 2 h, or transduced with lentivirus to silence or overexpress EZH1 or EZH2. Starved cells were stimulated with PDGF-BB (final 20 ng/ml) for 24 or 48 h before harvest for qRT-PCR or Western blot assay, respectively. Quantification: Mean ± SEM; n = 3 independent experiments. Statistics: one-way ANOVA with Bonferroni test, *P < 0.05, **P < 0.01. (A, B, C) Effect of pan-EZH1/2 inhibition on the expression of P57, cyclin-D1, and UHRF1. (D, E, F) Effect of EZH1 or EZH2 silencing on the expression of P57, cyclin-D1, and UHRF1. (G, H, I) Effect of increasing EZH1 or EZH2 on the expression of P57, cyclin-D1, and UHRF1. (J) ChIP-qPCR indicating H3K27ac or H3K4me1 binding at Ezh2 or Uhrf1. qPCR data were normalized to IgG control.

    Source data are available for this figure.

    Source Data for Figure 9[LSA-2021-01114_SdataF4_F8_F9_FS6.pdf]

  • Figure 10.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 10. Immunofluorescent detection of UHRF1 on artery cross sections.

    (A, B) Decrease in UHRF1 due to tamoxifen-induced BRD4 KO in wire-injured mouse femoral arteries. Neointima is demarcated between arrow heads. Scale bar: 50 μm. Fluorescence intensity was normalized to cell number. Quantification: Mean ± SEM; n = 5 mice. Statistics: nonparametric Mann–Whitney test following Shapiro–Wilk normality determination, *P < 0.05; r.u., relative unit. (C, D) Increase of UHRF1 after EZH1 or EZH2 overexpression in angioplasty-injured rat carotid arteries. Neointima is demarcated between arrow heads. Scale bar: 50 μm. Fluorescence intensity was normalized to cell number. Quantification: Mean ± SEM; n = 3 rats. Statistics: nonparametric Mann–Whitney test following Shapiro–Wilk normality determination, *P < 0.05 compared with GFP control; r.u., relative unit.

  • Figure S9.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S9. UHRF1 immunofluorescence localized in the nuclei of neointima cells.

    The pictures are high-mag versions of that presented in Fig 10C. Neointima is indicated between arrow heads. A, adventitia. M, media. N, neointima. Scale bar: 50 μm.

Supplementary Materials

  • Figures
  • Table S1 Mean coverage of ChIPseq peaks. Note: The gene intervals queried include the regions shown on the IGV graphs.

  • Table S2 Primers for Brd4−/− genotyping.

  • Table S3 siRNA or shRNA sequences for mouse and rat genes.

  • Table S4 Antibodies.

  • Table S5 Primer sequences for mouse and rat genes (qRT-PCR).

  • Table S6 Primer sequences for ChIP-qPCR.

  • Table S7 Bed file of ChIPseq peak regions.

PreviousNext
Back to top
Download PDF
Email Article

Thank you for your interest in spreading the word on Life Science Alliance.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Angioplasty induces epigenomic remodeling in injured arteries
(Your Name) has sent you a message from Life Science Alliance
(Your Name) thought you would like to see the Life Science Alliance web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Epigenomic remodeling upon neointima formation
Mengxue Zhang, Go Urabe, Hatice Gulcin Ozer, Xiujie Xie, Amy Webb, Takuro Shirasu, Jing Li, Renzhi Han, K Craig Kent, Bowen Wang, Lian-Wang Guo
Life Science Alliance Feb 2022, 5 (5) e202101114; DOI: 10.26508/lsa.202101114

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Epigenomic remodeling upon neointima formation
Mengxue Zhang, Go Urabe, Hatice Gulcin Ozer, Xiujie Xie, Amy Webb, Takuro Shirasu, Jing Li, Renzhi Han, K Craig Kent, Bowen Wang, Lian-Wang Guo
Life Science Alliance Feb 2022, 5 (5) e202101114; DOI: 10.26508/lsa.202101114
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
Issue Cover

In this Issue

Volume 5, No. 5
May 2022
  • Table of Contents
  • Cover (PDF)
  • About the Cover
  • Masthead (PDF)
Advertisement

Jump to section

  • Article
    • Abstract
    • Introduction
    • Results
    • Discussion
    • Materials and Methods
    • Data Availability
    • Acknowledgements
    • References
  • Figures & Data
  • Info
  • Metrics
  • Reviewer Comments
  • PDF

Subjects

  • Chromatin & Epigenetics

Related Articles

  • No related articles found.

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Lysosomal Ca2+ drives Lamtor1–MPRIP-mediated cell migration
  • RalGAP in pancreatic disease
  • Solithromycin binds in resistant S. aureus
Show more Research Article

Similar Articles

EMBO Press LogoRockefeller University Press LogoCold Spring Harbor Logo

Content

  • Home
  • Newest Articles
  • Current Issue
  • Archive
  • Subject Collections

For Authors

  • Submit a Manuscript
  • Author Guidelines
  • License, copyright, Fee

Other Services

  • Alerts
  • Bluesky
  • X/Twitter
  • RSS Feeds

More Information

  • Editors & Staff
  • Reviewer Guidelines
  • Feedback
  • Licensing and Reuse
  • Privacy Policy

ISSN: 2575-1077
© 2025 Life Science Alliance LLC

Life Science Alliance is registered as a trademark in the U.S. Patent and Trade Mark Office and in the European Union Intellectual Property Office.